March 19, 2025 — Intriguing observations on the effect of retatrutide on cancer progression in mice appeared Friday in NPJ Metabolic Health and Disease. Retatrutide is the first triple agonist to progress in clinical development for obesity. Lilly said recently that they expect to release phase three clinical trial data for it later this year – earlier than previously […]
February 10, 2025 — The remarkable advances of the last few years in understanding and responding to obesity all comes from insight into a place in your brain that’s about the size of an almond. It is your hypothalamus. In Nature last week, researchers from Cambridge and the Max Planck Institute published a detailed map of the human hypothalamus. […]
September 20, 2024 — This year, the Lasker-DeBakey Clinical Medical Research Award recognizes research on GLP-1 receptor biology that is revolutionizing obesity medicine. This is a revolution that is sending shockwaves through all of healthcare and indeed through society. Revolutions are uncomfortable and many people look at progress such as this with regretful nostalgia or outright fear. So we […]
September 2, 2024 — It’s true. We have been getting some pretty good news about GLP-1s lately. In persons with prediabetes and obesity, tirzepatide was 94% effective at preventing the development of diabetes. In the SELECT study, semaglutide for obesity might have cut COVID fatalities by a third. So a little exuberance about the potential of GLP-1 medicines is […]
August 20, 2024 — Semaglutide – under the banner of Ozempic – has set a revolution of obesity medicines in motion. Suddenly, all of the huffing and puffing about “treating obesity seriously” and “obesity as a disease” is moot. Facts on the ground are persuading people to re-orient their thinking about obesity faster than essays and advocacy campaigns ever […]
May 10, 2024 — Seeking better ways of coping with obesity has taken us on quite a twisted path. From more than 20 years we’ve been working on this disease, the last two have brought exponentially more change than we’ve ever seen. This week, in an outstanding report for the Atlantic, Daniel Engber offers up the clearest, most objective, […]
